ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes
LEXINGTON, Mass.--(BUSINESS WIRE)--Oct 21, 2023--Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the companyÄ¢¹½ÊÓÆµ phase 1b study of botensilimab (BOT, multifunctional immune activator) in combination with ...
